Amgen (AMGN) Reports AMG 416 Combo Phase 3 Met Primary Endpoint
Tweet Send to a Friend
Amgen (NASDAQ: AMGN) announced results from the head-to-head Phase 3 study comparing AMG 416 with cinacalcet for the treatment of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
